Bushra Yasin Abo Halawa

Ms. Bushra Yasin Abo Halawa

Qatar University, Biological Sciences Program, College of Arts and Sciences
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2022 in Journal of Travel Medicine
Verified
Journal Article
Open access
PDF file
Haissam Abou-SalehHaissam Abou-Saleh
Haissam Abou-Saleh
BHBushra Yasin Abo Halawa
Bushra Yasin Abo Halawa
SYSalma Younes
Salma Younes
NYNadin Younes
Nadin Younes
DADuaa Al-Sadeq
Duaa Al-Sadeq
Gheyath NasrallahGheyath Nasrallah
Gheyath Nasrallah
Waning protection against emerging SARS-CoV-2 variants by pre-existing antibodies elicited because of current vaccination or natural infection is a global concern. Whether this is due to the waning of immunity to SARS-COV-2 remains unclear. We aimed to investigate the dynamics of antibody isotype responses amongst vaccinated naïve (VN) and naturally infected (NI) individuals. We followed up antibody levels in COVID-19 messenger RNA (mRNA)-vaccinated subjects without prior infection (VN, n = 100) in two phases: phase-I (P-I) at ~ 1.4 and phase-II (P-II) at ~ 5.3 months. Antibody levels were compared with those of unvaccinated and naturally infected subjects (NI, n = 40) at ~ 1.7 (P-1) and 5.2 (P-II) months post-infection. Neutralizing antibodies (NTAb), anti-S-RBD-IgG, -IgM and anti-S-IgA isotypes were measured. The VN group elicited significantly greater antibody responses (P < 0.001) than the NI group at P-I, except for IgM. In the VN group, a significant waning in antibody response was observed in all isotypes. There was about an ~ 4-fold decline in NTAb levels (P < 0.001), anti-S-RBD-IgG (~5-fold, P < 0.001), anti-S-RBD-IgM (~6-fold, P < 0.001) and anti-S1-IgA (2-fold, P < 0.001). In the NI group, a significant but less steady decline was notable in S-RBD-IgM (~2-fold, P < 0.001), and a much smaller but significant difference in NTAb (<2-fold, P < 0.001) anti-S-RBD IgG (<2-fold, P = 0.005). Unlike the VN group, the NI group mounted a lasting anti-S1-IgA response with no significant decline. Anti-S1-IgA, which were ~ 3-fold higher in VN subjects compared with NI in P-1 (P < 0.001), dropped to almost the same levels, with no significant difference observed between the two groups in P-II. Whereas double-dose mRNA vaccination boosted antibody levels, vaccinated individuals’ ‘boost’ was relatively short-lived.

15 August 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
NYNadin Younes
Nadin Younes
DADuaa Al-Sadeq
Duaa Al-Sadeq
FSFarah M. Shurrab
Farah M. Shurrab
HAHadeel Al-Jighefee
Hadeel Al-Jighefee
Haissam Abou-SalehHaissam Abou-Saleh
Haissam Abou-Saleh
Gheyath NasrallahGheyath Nasrallah
Gheyath Nasrallah
Background: Limited commercial LFA assays are available to provide a reliable quantitative measurement of the total binding antibody units (BAU/mL) against the receptor-binding domain of the SARS-CoV-2 spike protein (S-RBD). Aim: This study aimed to evaluate the performance of the fluorescence LFA FinecareTM 2019-nCoV S-RBD test along with its reader (Model No.: FS-113) against the following reference methods: (i) the FDA-approved GenScript surrogate virus-neutralizing assay (sVNT); and (ii) three highly performing automated immunoassays: BioMérieux VIDAS®3, Ortho VITROS®, and Mindray CL-900i®. Methods: Plasma from 488 vaccinees was tested by all aforementioned assays. Fingerstick whole-blood samples from 156 vaccinees were also tested by FinecareTM. Results and conclusions: FinecareTM showed 100% specificity, as none of the pre-pandemic samples tested positive. Equivalent FinecareTM results were observed among the samples taken from fingerstick or plasma (Pearson correlation r = 0.9, p < 0.0001), suggesting that fingerstick samples are sufficient to quantitate the S-RBD BAU/mL. A moderate correlation was observed between FinecareTM and sVNT (r = 0.5, p < 0.0001), indicating that FinecareTM can be used for rapid prediction of the neutralizing antibody (nAb) post-vaccination. FinecareTM BAU results showed strong correlation with VIDAS®3 (r = 0.6, p < 0.0001) and moderate correlation with VITROS® (r = 0.5, p < 0.0001) and CL-900i® (r = 0.4, p < 0.0001), suggesting that FinecareTM can be used as a surrogate for the advanced automated assays to measure S-RBD BAU/mL.

25 January 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
FSFarah M. Shurrab
Farah M. Shurrab
DADuaa Al-Sadeq
Duaa Al-Sadeq
Haissam Abou-SalehHaissam Abou-Saleh
Haissam Abou-Saleh
Nader Al-DewikNader Al-Dewik
Nader Al-Dewik
AEAmira Ehab Elsharafi
Amira Ehab Elsharafi
Gheyath NasrallahGheyath Nasrallah
Gheyath Nasrallah
The currently authorized mRNA COVID-19 vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273, offer great promise for reducing the spread of the COVID-19 by generating protective immunity against SARS-CoV-2. Recently, it was shown that the magnitude of the neutralizing antibody (NAbs) response correlates with the degree of protection. However, the difference between the immune response in naïve mRNA-vaccinated and previously infected (PI) individuals is not well studied. We investigated the level of NAbs in naïve and PI individuals after 1 to 26 (median = 6) weeks of the second dose of BNT162b2 or mRNA-1273 vaccination. The naïve mRNA-1273 vaccinated group (n = 68) generated significantly higher (~2-fold, p ≤ 0.001) NAbs than the naïve BNT162b2 (n = 358) group. The P -vaccinated group (n = 42) generated significantly higher (~3-fold; p ≤ 0.001) NAbs levels than the naïve-BNT162b2 (n = 426). Additionally, the older age groups produced a significantly higher levels of antibodies than the young age group (<30) (p = 0.0007). Our results showed that mRNA-1273 generated a higher NAbs response than the BNT162b2 vaccine, and the PI group generated the highest level of NAbs response regardless of the type of vaccine.

1 July 2026 in Genes & Diseases
Verified
Journal Article
Open access
NANoura Aldous
Noura Aldous
AAAldana Alnesf
Aldana Alnesf
AEAhmed K. Elsayed
Ahmed K. Elsayed
BHBushra Yasin Abo Halawa
Bushra Yasin Abo Halawa
NANehad M. Alajez
Nehad M. Alajez
Essam M. AbdelalimEssam M. Abdelalim
Essam M. Abdelalim